A Rare Cause of Massive Upper Gastrointestinal Hemorrhage in Immunocompromised Host

Obai Abdullah, Nicole A. Pele, Yumei Fu, Imran Ashraf, Murtaza Arif, Matthew L. Bechtold, Ajitinder Grewal, Hazem T. Hammad

Abstract

Mucormycosis is an invasive and aggressive opportunistic fungal infection that usually presents with rhinocerebral or pulmonary involvement and rarely involves the gastrointestinal tract. The disease is acute with mortality rate up to 100%. A 68-year-old male was undergoing treatment at a local hospital for COPD exacerbation with IV steroids and antibiotics. Two weeks into his treatment he suddenly developed massive upper GI bleeding and hemodynamic instability that necessitated transfer to our tertiary care hospital for further treatment and management. An urgent upper endoscopy revealed multiple large and deep gastric and duodenal bulb ulcers with stigmata of recent bleeding. The ulcers were treated endoscopically. Biopsies showed fibrinopurulent debris with fungal organisms. Stains highlighted slightly irregular hyphae with rare septa and yeast suspicious for Candida. The patient was subsequently placed on fluconazole. Unfortunately, the patient’s general condition continued to worsen and he developed multiorgan failure and died. Autopsy revealed disseminated systemic mucormycosis. Most of the cases of gastrointestinal mucormycosis were reported from the tropics and few were reported in the United States. The disease occurs most frequently in immunocompromised individuals. The rare incidence of GI involvement, acute nature, severity and the problematic identification of the organisms on biopsies make ante-mortem diagnosis challenging. Treatment includes parenteral antifungals and debridement of the infected tissues. Gastroenterologists should be aware of this rare cause of gastrointestinal bleeding and understand the importance of communication with the reviewing pathologist so that appropriate, and often lifesaving, therapies can be administered in a timely manner.

Keywords: Invasive mucormycosis; Gastrointestinal bleed

Introduction

Mucormycosis is an invasive and aggressive opportunistic fungal infection that usually presents with rhinocerebral or pulmonary involvement and rarely involves the gastrointestinal tract. The disease is acute with mortality rate up to 100%. Herein we describe a rare case of disseminated invasive mucormycosis that presented with massive upper GI bleeding.

Case Report

A 68-year-old male was undergoing treatment at a local hospital for COPD exacerbation with IV steroids and antibiotics. Two weeks into his treatment he suddenly developed massive upper GI bleeding and hemodynamic instability that necessitated transfer to our tertiary care hospital for further treatment and management.

An urgent upper endoscopy revealed multiple large and deep gastric and duodenal bulb ulcers with stigmata of recent bleeding. The ulcers were treated endoscopically with epinephrine injection and bipolar cautery, and proton pump inhibitor therapy was initiated. Biopsies obtained from the gastric mucosa showed fibrinopurulent debris with fungal organisms. Periodic acid-Schiff and Grocott’s methanamine silver stains were performed which highlighted slightly irregular hyphae with rare septa and yeast suspicious for Candida. The patient was subsequently placed on fluconazole.

Unfortunately, the patient’s general condition continued
to worsen and he developed multiorgan failure including: altered mental status, respiratory failure, thyroid storm, atrial fibrillation, renal failure, and pancytopenia. He died 2 weeks later due to multiorgan failure at which time an autopsy revealed disseminated systemic mucormycosis with necrotizing hemorrhagic infarctions in the stomach (Fig.1, 2), lungs, kidneys, thyroid, and brain.

Discussion

Mucormycosis refers to several different diseases caused by fungi in the order Mucorales, which includes the species Mucor, Rhizopus, Absidia and Cunninghamella [1, 2], ubiquitous saprophytic molds found in soil and organic matter worldwide [3]. These rare fungal infections usually only occur in individuals with impaired immunity, diabetes mellitus, hematological or solid-organ malignancies, transplantation, neutropenia and steroid therapy [4].

The most common clinical presentation of mucormycosis is rhinocerebral [5] and pulmonary involvement [6]. Gastrointestinal infection with invasive mucor–mycosis is extremely rare [7]. All portions of the gastrointestinal tract can be involved, with the stomach, ileum, and colon most commonly affected. The organisms probably enter the host by way of the mouth [8]. Disseminated disease might occur and affect almost all body organs as in our case [9].

When gastrointestinal tract is involved, mucormycosis can present with nonspecific symptoms such as abdominal pain, nausea, and vomiting [10]; however, given its angioinvasive abilities, invasion of blood vessels can occur leading to hemorrhage and perforation as in our case [7, 11]. This clinical picture, along with epigastric distention, is the most frequent presentation [12]. Mortality of patients with GI mucormycosis is very high [12]. In a meta-analysis study of 929 cases of mucormycosis, mortality rate was 85% in patients with GI involvement [13].

Endoscopically, gastric mucormycosis can have the appearance of a white, fibrinous growth [7] or be associated with hemorrhage and necrosis [10]. A typical gastrointestinal lesion consists of a dark ulcer with sharply demarcated edges and with necrosis and thrombosis in adjacent vessels [14, 15]. Examination of the biopsy specimen with direct light without staining can sometimes establish the diagnosis within minutes after the procedure [16]. The organism has a characteristic morphology consisting of irregular, broad, ribbon-like nonseptate hyphae which branch at right-angles and can be seen invading tissue and vascular channels [17]. On occasion, the ribbon-like hyphae can twist and fold, resembling septa; and rarely true septa are present [18]. Angioinvasion was not identified in our endoscopic biopsies which may have been due to the limited size and superficial nature of the specimen.

Diagnosis is challenging, especially on scant tissue samples, and is complicated by distortion of the organism during tissue retrieval and processing. Significant pathological expertise is required to make the diagnosis [19]. If there is a strong suspicion of Mucorales infection, this information should be conveyed to the pathologist at the time of evaluation. The diagnosis is usually made by biopsy of the suspected area during surgery, endoscopy, or commonly postmortem at autopsy [7].

Hofman et al. [20] observed the usefulness of frozen section in rhinocerebral mucormycosis diagnosis and management on seven patients. In his observation, cytological imprints performed on surgical biopsies were thought to be less effective than frozen section for the immediate diagnosis of mucormycosis because of the presence of hemorrhages and necrotic tissue. However, in three of seven cases, typical Mucorales organisms stained by toluidine blue, haematoxylin and eosin, or Gomori Grocott’s methamine silver method could be cytologically demonstrated.

Interpretation of tissue cultures in these patients is a complicated and slow process. The organism is a common laboratory contaminant and may be destroyed during tissue processing rendering false positive and negative results, re-
respectively [21]. Organisms in tissue specimens with histopathologically identified mucormycosis often fail to grow in fungal cultures [19]. Roden et al. [13] reviewed 929 cases of reported mucormycosis between 1940 and 2003. In his review, only 50% culture positive patients were identified.

Most of the cases of gastrointestinal mucormycosis were reported from the tropics; however, the disease is increasingly becoming an iatrogenic and/or nosocomial problem in industrialized nations [7] and recent studies have reported dramatic increase in the incidence of mucormycosis [22-24]. Very few cases of gastrointestinal mucormycosis affecting adults have been reported in the United States [6, 7, 25].

Systemic amphotericin B is the mainstay of treatment. Reversal of underlying medical disease and often surgical debridement of the infected tissues are necessary for successful management [12].

Conclusion

Most of the cases of gastrointestinal mucormycosis were reported from the tropics and few were reported in the United States. The disease occurs most frequently in immunocompromised individuals. The rare incidence of GI involvement, acute nature, severity and the problematic identification of the organisms on biopsies make antemortem diagnosis challenging. Treatment includes parenteral antifungals (amphotericin B) and debridement of the infected tissues. Advances in medical therapies have improved survival for many disease states which have resulted in an ever increasing number of immunocompromised patients. It is likely that we will see a corresponding increase in the incidence of Mucormycosis. Gastroenterologists should be aware of this rare cause of bleeding gastric and duodenal ulcers and understand the importance of communication with the reviewing pathologist so that appropriate, and often lifesaving, therapies can be administered in a timely manner.

References

1. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20(3):581-607, vi.
2. Mucormycosis. Ann Intern Med. 1980;93(1):93-108.
3. Li KW, Wen TF, Li GD. Hepatic mucormycosis mimicking hilar cholangiocarcinoma: a case report and literature review. World J Gastroenterol. 2010;16(8):1039-1042.
4. Lo OS, Law WL. Ileocolonic mucormycosis in adult immunocompromised patients: a surgeon’s perspective. World J Gastroenterol. 2010;16(9):1165-1170.
5. Singh N, Gayowski T, Singh J, Yu VL. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis. 1995;20(3):617-620.
6. Brown J. Zygomycosis: an emerging fungal infection. Am J Health Syst Pharm. 2005;62(24):2593-2596.
7. Mitre MC MR, Atkinson DP, Adurty R, Nathan G, Veynovich B. Invasive Gastric Mucormycosis. Gastroenterology and Hepatology. 2005;12(1):128–9.
8. Maravi-Poma E, Rodriguez-Tudela JL, de Jalon JG, Manrique-Larralde A, Torroba L, Urtasun J, Salvador B, et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med. 2004;30(4):724-728.
9. Ingram CW, Sennesh J, Cooper JN, Perfect JR. Disseminated zygomycosis: report of four cases and review. Rev Infect Dis. 1989;11(5):741-754.
10. Devlin SM, Hu B, Ippoliti A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn’s disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci. 2007;52(9):2078-2081.
11. Spellberg B, Edwards J, Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-569.
12. Shiva Prasad BN, Shenoy A, Nataraj KS. Primary gastrointestinal mucormycosis in an immunocompetent person. J Postgrad Med. 2008;54(3):211-213.
13. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653.
14. Timm J, Baker J, Gardner G. Gastrointestinal mucormycosis in a renal transplant patient. Can J Gastroenterol. 2001;15(4):269-271.
15. Ju JH, Park HS, Shin MJ, Yang CW, Kim YS, Choi YJ, Song HJ, et al. Successful treatment of massive lower gastrointestinal bleeding caused by mixed infection of cytomegalovirus and mucormycosis in a renal transplant recipient. Am J Nephrol. 2001;21(3):232-236.
16. Meyers BR, Wormser G, Hirschman SZ, Blitzer A. Rhi-
17. Pollock RA, Pratt RC, Shulman JA, Turner JS. Nasal mucormycosis: early detection and treatment without radical surgery or amphotericin B. South Med J. 1975;68(10):1279-1282.
18. Moore GS, Jaciow, D.M. Mycology For The Clinical Laboratory. Reston Publishing Company. 1979.
19. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49(6):2151-2153.
20. Hofman V, Castillo L, Betis F, Guevara N, Gari-Tous-
saint M, Hofman P. Usefulness of frozen section in rhinocerebral mucormycosis diagnosis and management. Pathology. 2003;35(3):212-216.
21. Ibrahim AS EJJ, Filler SG. Zygomycoses. Clinical Mycology. Ed. Dismukes WE, Pappas PG, Sobel JD. New York, NY. Oxford University Press. 2003.
22. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350-1360.
23. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909-917.
24. Gleissner B, Schilling A, Anagnostopoulos I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma. 2004;45(7):1351-1360.
25. Johnson CB, Ahmeti M, Tyroch AH, Zuckerman MJ, Hakim MN. Gastric mucormycosis as a cause of life-threatening upper gastrointestinal bleeding in a trauma patient. Am Surg. 2010;76(7):E76-77.